Benign cartilaginous tumors of bone: From morphology to somatic and germ-line genetics

Advances in Anatomic Pathology

Volumn 16, Issue 5, 2009, Pages 307-315

  Romeo, Salvatore ^a   Hogendoorn, Pancras C W ^b   Dei Tos, Angelo Paolo ^a  

^a TREVISO REGIONAL HOSPITAL   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Benign; Bone tumors; Cartilage; Differential diagnosis; EXT; Genetics

Indexed keywords

CARTILAGE TUMOR; CHONDROBLASTOMA; CHONDROMYXOID FIBROMA; DIFFERENTIAL DIAGNOSIS; ENCHONDROMA; ENCHONDROMATOSIS; GENE MUTATION; GERM LINE; HEREDITARY MULTIPLE EXOSTOSIS; HUMAN; MORPHOLOGY; MYXOMA; OSTEOCHONDROMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; TUMOR GENE;

ADOLESCENT; ADULT; BONE NEOPLASMS; CARTILAGE; CHILD; CHONDROBLASTOMA; CHONDROMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBROMA; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; N-ACETYLGLUCOSAMINYLTRANSFERASES; OSTEOCHONDROMA; TRANSLOCATION, GENETIC;

EID: 69449102783     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181b506a1     Document Type: Review

References (94)

1. WHO. Cartilage tumours. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:234-257.
2. Porter GA, Gurley MA, Roth SI. Bone. In: Sternberg SS, ed. Histology for Pathologists. 2nd ed. Philadelphia: Lippincott-Raven; 1997:85-105.
3. Bovée JVMG, Hogendoorn PCW. Cartilage-forming Tumours of Bone and Soft Tissue and Their Differential Diagnosis. Curv Diagn Pathol. 2001;7:223-234. (Pubitemid 34101141)
4. Bell WC, Klein MJ, Pitt MJ, et al. Molecular pathology of chondroid neoplasms: part 2, malignant lesions. Skeletal Radiol. 2006;35:887-894. (Pubitemid 44697624)
5. Bell WC, Klein MJ, Pitt MJ, et al. Molecular pathology of chondroid neoplasms: part 1, benign lesions. Skeletal Radiol. 2006;35:805-813. (Pubitemid 44501961)
6. van den Berg H, Kroon HM, Slaar A, et al. Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration "PALGA." J Pediatr Orthop. 2008;28:29-35.
7. Jaffe HL. Tumors and Tumorous Conditions of the Bones and Joints. Philadelphia: Lea & Febirger; 1958.
8. Khurana J, Abdul-Karim F, Bovée JVMG. Osteochondroma. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:234-236.
9. Hameetman L, Bovée JVMG, Taminiau AHM, et al. Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management. Hered Cancer in Clin Pract. 2004;2:161-173.
10. Hameetman L, Szuhai K, Yavas A, et al. The Role of EXT1 in non hereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst. 2007;99:396-406. (Pubitemid 47073483)
11. Jaffe N, Ried HL, Cohen M, et al. Radiation induced osteochondroma in long-term survivors of childhood cancer. Int J Radiat Oncol Biol Phys. 1983;9:665-670.
12. Bordigoni P, Turello R, Clement L, et al. Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases. Bone Marrow Transplant. 2002;29:611-614. (Pubitemid 34537723)
13. Taitz J, Cohn RJ, White L, et al. Osteochondroma after total body irradiation: an age-related complication. Pediatr Blood Cancer. 2004;42:225-229. (Pubitemid 38235072)
14. Trevor D. Tarso-epiphysial aclasis; a congenital error of epiphysial development. J Bone Joint Surg Br. 1950;32-B:204-213.
15. Bovée JVMG, Hameetman L, Kroon HM, et al. EXT-related pathways are not involved in pathogenesis of dysplasia epiphysealis hemimelica and metachondromatosis. J Pathol. 2006;209:411-419. (Pubitemid 43997751)
16. Eefting D, Schrage YM, Geirnaerdt MJ, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol. 2009;33:50-57.
17. Geirnaerdt MJ, Bloem JL, Eulderink F, et al. Cartilaginous tumors: correlation of gadolinium-enhanced MR imaging and histopathologic findings. Radiology. 1993;186:813-817. (Pubitemid 23073527)
18. Hameetman L, Kok P, Eilers PHC, et al. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch. 2005;446:430-437. (Pubitemid 40674851)
19. Bovée JVMG, Van den Broek LJCM, Cleton-Jansen AM, et al. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest. 2000;80:1925-1933.
20. Matsuno T, Ichioka Y, Yagi T, et al. Spindle-cell sarcoma in patients who have osteochondromatosis. A report of two cases. J Bone Joint Surg Am. 1988;70:137-141. (Pubitemid 18054908)
21. Tsuchiya H, Morikawa S, Tomita K. Osteosarcoma arising from a multiple exostoses lesion: case report. Jpn J Clin Oncol. 1990;20:296-298.
22. van Lerberghe E, Van Damme B, van Holsbeeck M, et al. Case report 626: osteosarcoma arising in a solitary osteochondroma of the femur. Skeletal Radiol. 1990;19:594-597.
23. Nojima T, Yamashiro K, Fujita M, et al. A case of osteosarcoma arising in a solitary osteochondroma. Acta Orthop Scand. 1991;62:290-292.
24. Bovée JVMG, Sakkers RJ, Geirnaerdt MJ, et al. Intermediate grade osteosarcoma and chondrosarcoma arising in an osteochondroma. A case report of a patient with hereditary multiple exostoses. J Clin Pathol. 2002;55:226-229.
25. Lucas DR, Bridge JA. Chondromas: enchondroma, periosteal chondroma, and enchondromatosis. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:237-240.
26. Ollier M. De la dyschondroplasia. Bull Soc Chir Lyon. 1899;3:22-23.
27. Maffucci A. Di un caso encondroma ed angioma multiplo. Movimento medico-chirurgico, Napoli. 1881;3:399-412; 565-575.
28. Bovée JVMG, Van der Heul RO, Taminiau AHM, et al. Chondrosarcoma of the phalanx: a locally aggressive lesion with minimal metastatic potential. A report of 35 cases and a review of the literature. Cancer. 1999;86:1724-1732.
29. Geirnaerdt MJA, Hermans J, Bloem JL, et al. Usefulness of radiography in differentiating enchondroma from central grade I chondrosarcoma. AJR Am J Roentgenol. 1997;169:1097-1104. (Pubitemid 27406912)
30. Geirnaerdt MJ, Hogendoorn PCW, Bloem JL, et al. Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology. 2000;214:539-546.
31. Kilpatrick SE, Parisien M, Bridge JA. Chondroblastoma. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:241-242.
32. Huang L, Cheng YY, Chow LT, et al. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol. 2003;56:116-120. (Pubitemid 36461472)
33. Aigner T, Loos S, Inwards C, et al. Chondroblastoma is an osteoid-forming, but not cartilage-forming neoplasm. J Pathol. 1999;189:463-469.
34. Soder S, Oliveira AM, Inwards CY, et al. Type II collagen, but not aggrecan expression, distinguishes clear cell chondrosarcoma and chondroblastoma. Pathology. 2006;38:35-38. (Pubitemid 43259250)
35. Bousdras K, O'Donnell P, Vujovic S, et al. Chondroblastomas but not chondromyxoid fibromas express cytokeratins: an unusual presentation of a chondroblastoma in the metaphyseal cortex of the tibia. Histopathology. 2007;51:414-416. (Pubitemid 47301615)
36. Ostrowski ML, Spjut HJ, Bridge JA. Chondromyxoid fibroma. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:243-245.
37. Gherlinzoni F, Rock M, Picci P. Chondromyxoid fibroma. The experience at the Istituto Ortopedico Rizzoli. J. Bone Joint Surg Am. 1983;65:198-204.
38. Wu CT, Inwards CY, O'Laughlin S, et al. Chondromyxoid fibroma of bone: a clinicopathologic review of 278 cases. Hum Pathol. 1998;29:438-446. (Pubitemid 28213462)
39. Romeo S, Bovée JVMG, Grogan S, et al. Chondromyxoid fibroma resembles in vitro chondrogenesis, though differs in expression of signalling molecules. J Pathol. 2005;206:135-142. (Pubitemid 40754016)
40. Romeo S, Eyden B, Prins FA, et al. TGF-beta1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone. J Pathol. 2006;208:26-34. (Pubitemid 43025701)
41. Soder S, Inwards C, Muller S, et al. Cell biology and matrix biochemistry of chondromyxoid fibroma. Am J Clin Pathol. 2001;116:271-277. (Pubitemid 33044333)
42. Romeo S, Oosting J, Rozeman LB, et al. The role of noncartilage-specific molecules in differentiation of cartilaginous tumors: lessons from chondroblastoma and chondromyxoid fibroma. Cancer. 2007;110:385-394. (Pubitemid 47121900)
43. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7:233-245. (Pubitemid 46480968)
44. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003;3:685-694.
45. Suva ML, Cironi L, Riggi N, et al. Sarcomas: genetics, signalling, and cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase mutations. J Pathol. 2007;213:117-130. (Pubitemid 47612234)
46. Riggi N, Cironi L, Suva ML, et al. Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. J Pathol. 2007;213:4-20. (Pubitemid 47354561)
47. Bovée JVMG. Multiple osteochondromas. Orphanet J Rare Dis. 2008;3:3.
48. Stickens D, Clines G, Burbee D, et al. The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet. 1996;14:25-32. (Pubitemid 26301543)
49. Wuyts W, Van Hul W, Wauters J, et al. Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet. 1996;5:1547-1557. (Pubitemid 26328870)
50. Ahn J, Ludecke H-J, Lindow S, et al. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet. 1995;11:137-143.
51. Cook A, Raskind W, Blanton SH, et al. Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet. 1993;53:71-79. (Pubitemid 23313737)
52. Raskind WH, Conrad EU III, Matsushita M, et al. Evaluation of locus heterogeneity and EXT1 mutations in 34 families with hereditary multiple exostoses. Hum Mutat. 1998;11:231-239. (Pubitemid 28132880)
53. Seki H, Kubota T, Ikegawa S, et al. Mutation frequencies of EXT1 and EXT2 in 43 Japanese families with hereditary multiple exostoses. Am J Med Genet. 2001;99:59-62. (Pubitemid 32121586)
54. Xu L, Xia J, Jiang H, et al. Mutation analysis of hereditary multiple exostoses in the Chinese. Hum Genet. 1999;105:45-50. (Pubitemid 29396963)
55. Park KJ, Shin K-H, Ku J-L, et al. Germline mutations in the EXT1 and EXT2 genes in Korean patients with hereditary multiple exostoses. J Hum Genet. 1999;44:230-234.
56. Wuyts W, Van Hul W, De Boulle K, et al. Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses. Am J Hum Genet. 1998;62:346-354. (Pubitemid 28110777)
57. Bridge JA, Nelson M, Orndal C, et al. Clonal karyotypic abnormalities of the hereditary multiple exostoses chromosomal loci 8q24.1 (EXT1) and 11p11-12 (EXT2) in patients with sporadic and hereditary osteochondromas. Cancer. 1998;82:1657-1663. (Pubitemid 28208914)
58. Mertens F, Rydholm A, Kreicbergs A, et al. Loss of chromosome band 8q24 in sporadic osteocartilaginous exostoses. Genes Chromosomes Cancer. 1994;9:8-12. (Pubitemid 24007490)
59. Bovée JVMG, Cleton-Jansen AM, Wuyts W, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet. 1999;65:689-698. (Pubitemid 30468713)
60. Feely MG, Boehm AK, Bridge RS, et al. Cytogenetic and molecular cytogenetic evidence of recurrent 8q24.1 loss in osteochondroma. Cancer Genet Cytogenet. 2002;137:102-107.
61. McCormick C, Duncan G, Goutsos KT, et al. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA. 2000;97:668-673. (Pubitemid 30070367)
62. Senay C, Lind T, Muguruma K, et al. The EXT1/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis. EMBO Rep. 2000;1:282-286.
63. Simmons AD, Musy MM, Lopes CS, et al. A direct interaction between EXT proteins and glycosyltransferases is defective in hereditary multiple exostoses. Hum Mol Genet. 1999;8:2155-2164.
64. McCormick C, Duncan G, Tufaro F. New perspectives on the molecular basis of hereditary bone tumours. Mol Med Today. 1999;5:481-486. (Pubitemid 29491448)
65. Lind T, Tufaro F, McCormick C, et al. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273:26265-26268.
66. Bovée JVMG, Cleton-Jansen AM, Taminiau AHM, et al. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol. 2005;6:599-607.
67. Hameetman L, David G, Yavas A, et al. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol. 2007;211:399-409. (Pubitemid 46332551)
68. Mertens F, Unni KK. Enchondromatosis: Ollier disease and Maffucci syndrome. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:356-357.
69. Cohen MM Jr, Siegal GP. McCune-Albright syndrome. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:357-359.
70. Hopyan S, Gokgoz N, Poon R, et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet. 2002;30:306-310. (Pubitemid 34887690)
71. Couvineau A, Wouters V, Bertrand G, et al. PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum Mol Genet. 2008;17:2766-2775.
72. Rozeman LB, Sangiorgi L, Bruijn IH, et al. Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Hum Mutat. 2004;24:466-473. (Pubitemid 39664600)
73. Rozeman LB, Hameetman L, Cleton-Jansen AM, et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol. 2005;205:476-482. (Pubitemid 40361336)
74. Rozeman LB, Hameetman L, van Wezel T, et al. cDNA expression profiling of central chondrosarcomas: Ollier disease resembles solitary tumors and alteration in genes coding for energy metabolism with increasing grade. J Pathol. 2005;207:61-71. (Pubitemid 41200715)
75. Buddingh EP, Naumann S, Nelson M, et al. Cytogenetic findings in benign cartilaginous neoplasms. Cancer Genet Cytogenet. 2003;141:164-168. (Pubitemid 36269219)
76. Bridge JA, Persons DL, Neff JR, et al. Clonal karyotypic aberrations in enchondromas. Cancer Detect Prev. 1992;16:215-219.
77. Bridge JA, Bhatia PS, Anderson JR, et al. Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous lesions. Cancer Genet Cytogenet. 1993;69:79-90. (Pubitemid 23313843)
78. Mandahl N, Willen H, Rydholm A, et al. Rearrangement of band q13 on both chromosomes 12 in a periosteal chondroma. Genes Chromosomes Cancer. 1993;6:121-123. (Pubitemid 23064480)
79. Dahlen A, Mertens F, Rydholm A, et al. Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas. Mod Pathol. 2003;16:1132-1140. (Pubitemid 37414208)
80. Rozeman LB, Szuhai K, Schrage YM, et al. Array-comparative genomic hybridization of central chondrosarcoma-Identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations. Cancer. 2006;107:380-388. (Pubitemid 44036568)
81. Ozisik YY, Meloni AM, Spanier SS, et al. Deletion 1p in a lowgrade chondrosarcoma in a patient with Ollier disease. Cancer Genet Cytogenet. 1998;105:128-133.
82. Zack P, Beighton P. Spondyloenchondromatosis: syndromic identity and evolution of the phenotype. Am J Med Genet. 1995;55:478-482.
83. Le Merrer M, Fressinger P, Maroteaux P. Genochondromatosis. J Med Genet. 1991;28:485-489.
84. Odink AE, van Asperen CJ, Vandenbroucke JP, et al. An association between cartilaginous tumours and breast cancer in the national pathology registration in The Netherlands points towards a possible genetic trait. J Pathol. 2001;193:190-192.
85. Cleton-Jansen AM, Timmerman MC, Van de Vijver MJ, et al. A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. Lab Invest. 2004;84:191-202.
86. Cuvelier C, Roels HJ. Cytophotometric studies of the nuclear DNA content in cartilaginous tumors. Cancer. 1979;44:1363-1374. (Pubitemid 10197410)
87. Swarts SJ, Neff JR, Johansson SL, et al. Significance of abnormalities of chromosomes 5 and 8 in chondroblastoma. Clin Orthop. 1998;349:189-193.
88. Mark J, Wedell B, Dahlenfors R, et al. Human benign chondroblastoma with a pseudodiploid stemline characterized by a complex and balanced translocation. Cancer Genet Cytogenet. 1992;58:14-17.
89. Sjogren H, Orndal C, Tingby O, et al. Cytogenetic and spectral karyotype analyses of benign and malignant cartilage tumours. Int J Oncol. 2004;24:1385-1391.
90. Van Zelderen-Bhola SL, Bovée JVMG, Wessels JW, et al. Ring chromosome 4 as sole anomaly in a chondroblastoma. A case report and review of the literature. Cancer Genet Cytogenet. 1998;105:109-112.
91. Mitelman F, Johansson B, Mertens F. Mitelman Database of Chromosme Aberrations in Cancer. 2009. http://cgap.nci.nih.gov/Chromosomes/.
92. Armah HB, McGough RL, Goodman MA, et al. Chondromyxoid fibroma of rib with a novel chromosomal translocation: a report of four additional cases at unusual sites. Diagn Pathol. 2007;2:44.
93. Smith CA, Magenis RE, Himoe E, et al. Chondromyxoid fibroma of the nasal cavity with an interstitial insertion between chromosomes 6 and 19. Cancer Genet Cytogenet. 2006;171:97-100. (Pubitemid 44751177)
94. Granter SR, Renshaw AA, Kozakewich HP, et al. The pericentromeric inversion, inv (6)(p25q13), is a novel diagnostic marker in chondromyxoid fibroma. Mod Pathol. 1998;11:1071-1074.